Sunshine Biopharma (SBFM) Q1 2024 Earnings
SBFM·Reported May 20, 2024·Before market open
Sunshine Biopharma reported Q1 2024 revenue of $7.5M, beat analyst consensus of $7.0M by $541.0K. Diluted EPS came in at $-40.00, missed the $-1.04 consensus by $38.96.
Revenue
$7.5Mbeat by $541.0K
Consensus: $7.0MDiluted EPS
$-40.00missed by $38.96
Consensus: $-1.04
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Sunshine Biopharma's Q1 2024 earnings report.
Sunshine Biopharma (SBFM) reported Q1 2024 earnings on May 20, 2024 before market open.
Sunshine Biopharma reported revenue of $7.5M and diluted EPS of $-40.00 for Q1 2024.
Revenue beat the consensus estimate of $7.0M by $541.0K. EPS missed the consensus estimate of $-1.04 by $38.96.
You can read the 10-Q periodic report (0001683168-24-003688) directly on SEC EDGAR. The filing index links above go to sec.gov.